Ependymoma Clinical Trials 2023

Browse 55 Ependymoma Medical Studies Across 137 Cities

1 Phase 3 Trial · 1565 Ependymoma Clinics

Reviewed by Michael Gill, B. Sc.
10 Ependymoma Clinical Trials Near Me
Top Hospitals for Ependymoma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
21Active Trials
24All Time Trials for Ependymoma
2009First Ependymoma Trial
Image of Children's Hospital Los Angeles in California.
Children's Hospital Los Angeles
Los Angeles
19Active Trials
23All Time Trials for Ependymoma
1997First Ependymoma Trial
Image of Cincinnati Children's Hospital Medical Center in Ohio.
Cincinnati Children's Hospital Medical Center
Cincinnati
18Active Trials
27All Time Trials for Ependymoma
2003First Ependymoma Trial
Image of Children's Hospital Colorado in Colorado.
Children's Hospital Colorado
Aurora
17Active Trials
20All Time Trials for Ependymoma
2010First Ependymoma Trial
Image of Arnold Palmer Hospital for Children in Florida.
Arnold Palmer Hospital for Children
Orlando
17Active Trials
19All Time Trials for Ependymoma
2004First Ependymoma Trial
Top Cities for Ependymoma Clinical Trials
Image of New York in New York.
New York
56Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Orlando in Florida.
Orlando
48Active Trials
Arnold Palmer Hospital for ChildrenTop Active Site
Ependymoma Clinical Trials by Phase of Trial
N/A Ependymoma Clinical Trials
2Active Ependymoma Clinical Trials
2Number of Unique Treatments
10Number of Active Locations
Ependymoma Clinical Trials by Age Group
< 18 Ependymoma Clinical Trials
1Active Ependymoma Clinical Trials
Most Recent Ependymoma Clinical TrialsTop Treatments for Ependymoma Clinical Trials
Treatment Name
Active Ependymoma Clinical Trials
All Time Trials for Ependymoma
First Recorded Ependymoma Trial
ONC206
2
2
2020
Pharmacological Study
2
9
2010
Ibrutinib
1
1
2022
SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
1
1
2019
Partial Radiation
1
1
2019

What Are Ependymoma Clinical Trials?

Ependymoma can be best described as a primary CNS tumor because it starts in the spinal cord or brain. It affects the ependymal cells responsible for lining the passageways from where cerebrospinal fluid flows to nourish the brain. The condition can affect people of all ages. However, it is more common in children than adults. It is known as the third most common type of CNS tumor in children. Though it is a progressive condition, Ependymoma doesn't spread or affect other body parts. It has three grades:

Grade 1: Myxopapillary Ependymoma is a low-grade tumor. The condition is characterized by slow tumor cell growth, commonly in the spine.

Grade 2- Classic Ependymoma is also a low-grade tumor occurring in the brain or spine

Grade 3: Anaplastic Ependymoma is a cancerous and fast-growing tumor occurring most commonly in the brain. It can recur after treatment.

Symptoms vary on tumor size, location, and patient's age. The condition may cause neck pain, blurry vision, muscle weakness, nausea, seizures, and headaches in adults and children. In babies, symptoms may include vomits, sleeplessness, irritability, and irregular size of the head.

Ependymoma clinical trials are scientific investigations of different anti-cancer treatments and medications, their efficacy, safety, and after-effects. These trials aim to find the best treatment to alleviate symptoms and help improve the quality of life of cancer patients.

Why Is Ependymoma Being Studied Through Clinical Trials?

Statistics by Cancer.gov show that approximately 13,294 individuals currently live with Ependymoma in the US. It is more common in non-Hispanic and white people. Nearly 1,098 individuals are diagnosed with Ependymoma annually. The 5-year Ependymoma survival rate is about 83.9 percent. Also, among other types of CNS tumors diagnosed, Ependymoma makes up about four percent of diagnoses in adolescents between 15 and 19 and six percent in infants and young children.

Institutions and researchers are conducting Ependymoma clinical trials to understand the actual cause of the condition and find a cure. Moreover, these trials are a way to improve the understanding of Ependymoma and gain more insights. This is much needed to find appropriate treatments for different grades of Ependymoma and increase the survival rate of patients.

What Are the Types of Treatments Available for Ependymoma?

There are multiple treatments available for Ependymoma. Depending on the tumor's grade, location, and age of the patient, the healthcare provider may determine the best treatment. Treatments for Ependymoma may be used separately or in combination. These include:

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy

What Are Some Recent Breakthrough Clinical Trials for Ependymoma?

2013: Research on Conformal Radiation Treatment for Ependymoma in Children - The study focused on assessing the treatment approach of the surgical invention with radiation therapy for children below three years. The research included 153 pediatric participants median age of 2.9. It provided new benchmarks for disease control; and a unified approach to treating Ependymoma, suggesting the inclusion of surgery and conformal and post-operative irradiation in children below three years.

2020- A Study of Dose Dense Lapatinib and Temozolomide for Recurrent, Low-Grade, and Spinal Cord-Related Ependymoma Phase II

In this phase II study, researchers studied the clinical dosage of TMZ (temozolomide) and lapatinib. The study included patients aged 18 and above with grade 3 Ependymoma. It was concluded that the treatment had a disease-control response and alleviated symptoms.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: August 27th, 2023

References1 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019032 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/314019033 Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5. https://pubmed.ncbi.nlm.nih.gov/175510114 Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. https://pubmed.ncbi.nlm.nih.gov/151263725 Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083. https://pubmed.ncbi.nlm.nih.gov/151263726 Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5. https://pubmed.ncbi.nlm.nih.gov/175510117 Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. https://pubmed.ncbi.nlm.nih.gov/266709718 Golubovskaya V. CAR-T Cells Targeting Immune Checkpoint Pathway Players. Front Biosci (Landmark Ed). 2022 Apr 2;27(4):121. doi: 10.31083/j.fbl2704121. Review. https://pubmed.ncbi.nlm.nih.gov/354686809 Golubovskaya V. CAR-T Cells Targeting Immune Checkpoint Pathway Players. Front Biosci (Landmark Ed). 2022 Apr 2;27(4):121. doi: 10.31083/j.fbl2704121. https://pubmed.ncbi.nlm.nih.gov/3546868010 Lang F, Liu Y, Chou FJ, Yang C. Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 2021 Dec;228:107922. doi: 10.1016/j.pharmthera.2021.107922. Epub 2021 Jun 23. Review. https://pubmed.ncbi.nlm.nih.gov/34171339